Improving Quality of Life in Men and Women With Overweight or Obesity

Obesity Clinical Trial

Official title:

Randomized, Controlled Trial of a Weight Loss Intervention in Improving Quality of Life in Men and Women With Overweight or Obesity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04871295
• Other study ID #: 00048812
• Status: Completed
• Phase: N/A
• Start date: April 15, 2021
• Est. completion date: February 15, 2022

Study information

• Verified date: November 2023
• Source: Noom Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of the Noom Healthy Weight Program, a digital behavior change weight loss intervention, on quality of life as measured both by self-report and objective measures, compared to a waitlist control condition.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 370
• Est. completion date: February 15, 2022
• Est. primary completion date: February 15, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Able to understand and provide informed consent

• 18-65 years old

• Self-report of good health (physical and mental)

• Not diagnosed with diabetes

• Overweight or obesity (BMI = 25)

• Able to meet our criteria of adherence to the program (at least 1 engagement per week on one of the following: logged exercise, logged meals, steps, weigh-ins, coach messages, read articles, and days with at least one weigh-in.)

• For females

• Not within the 6 months postpartum time frame

• Not planning to become pregnant in the next 5 months.

Exclusion Criteria:

• Inability or unwillingness of a participant to give written informed consent

• Currently taking medication which affects sleep or heart rate (e.g., (i) central nervous system stimulants, (ii) respiratory medications, (iii) antihistamines, (iv) central acting hormones (e.g. corticosteroids, thyroid), (v) high-dose anticholinergics, (vi) and cannot be using the maximum recommended dose for antihypertensive medications or use of multiple antihypertensive medications)

• Current diagnosed mental health condition (except mild anxious or depressive symptoms)

• Current diagnosed sleep disorder or condition not related to obesity (e.g., narcolepsy)

• Currently pregnant or = 6 months postpartum

• Currently participating in shift work and/or have travelled between time zones in the last month

• Presence of a condition or abnormality that in the opinion of the Investigator would compromise the quality of the data; E.g., evidence of an eating disorder, major chronic condition

Related Conditions & MeSH terms

• Health Behavior
• Obesity
• Overweight
• Overweight and Obesity
• Quality of Life

Intervention

Behavioral:
• Noom Healthy Weight
Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.

Locations

Country	Name	City	State
United States	Noom	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Noom Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	COVID status	COVID health questionnaire	4 months
Primary	Weight	Self Reported	4 months
Primary	In app engagement measures	Self reported and automatically recorded	4 months
Primary	Stress	Measured via heart rate variability; Data will be collected with a wearable tracking device (Oura Ring). Heart rate variability (HRV) measures the specific changes in time (or variability) between successive heart beats. The time between beats is measured in milliseconds (ms) and is called an "R-R interval" or "inter-beat interval (IBI).	4 months
Secondary	Self Reported Perceived Stress	Perceived Stress Scale (PSS) Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress	4 months
Secondary	Sleep Quality	Pittsburgh Sleep Quality Index (PSQI); The 19 self-rated items are combined to form seven "component" scores, each of which has a range of 0-3 points. In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. The seven component scores are then added to yield one "global" score, with a range of 0-21 points, "0" indicating no difficulty and "21" indicating severe difficulties in all areas.	4 months
Secondary	Sleep Impact	Adult Sickle Cell Quality of Life Measurement (ASCQ-Me); 5 point rating scale ranging from never - always.	4 months
Secondary	Sleep Score	Measured via a wearable health tracking device (Oura Ring). Sleep score consists of: Total sleep time, time in bed, sleep efficiency, and resting heart rate.	4 months
Secondary	Appetite and food craving	Food Cravings Questionnaire-State; he Food Cravings Questionnaire-State (FCQ-S) measures the intensity of momentary food craving. The questionnaire has 15 items and response categories range from 1 = strongly disagree to 5 = strongly agree	4 months
Secondary	Reward-related eating	Reward based eating scale (RED-9); A validated, 9-item index that captures reward-based eating drive as a single factor	4 months
Secondary	Perceived physical and mental health over time	Reported via the Health-related quality of life (HRQoL) survey; A multi-dimensional concept that includes domains related to physical, mental, emotional, and social functioning. It goes beyond direct measures of population health, life expectancy, and causes of death, and focuses on the impact health status has on quality of life.; 85 = Very good quality of life. 70 = Good quality of life. 57.5 = Moderately good quality of life.	4 months
Secondary	Depression and anxiety	Depression Anxiety Stress Scales (DASS); The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress.; Scoring: Normal; Depression: 0-9; Anxiety: 0-7; Stress: 0-14; Mild; Depression: 10-13; Anxiety: 8-9; Stress: 15-18; Moderate; Depression: 14-20; Anxiety: 10-14; Stress: 19-25; Severe; Depression: 21-27; Anxiety: 15-19; Stress: 26-33; Extremely severe; Depression: 28+; Anxiety: 20+; Stress: 34+	4 months